Sequential intervention of xinGengSanFang granule in patients with acute ST segment elevation myocardial infarction: a randomized, controlled, open label, multicenter clinical trial

Authors
Category Primary study
Registry of TrialsITMCTR
Year 2022
INTERVENTION: control group:Do not use any traditional Chinese medicine;Treatment group:sequential treatment of XinGengSanFang granules; CONDITION: acute ST segment elevation myocardial infarction PRIMARY OUTCOME: LVEF;LVEDV;LVESV; INCLUSION CRITERIA: a)Aged 18 years or over and under 85 years b)Presence of STEMI who has successfully coronary recanalization by PCI within 12 h after the symptom onset; c)Willingness to provide informed consent prior to enrollment;
Epistemonikos ID: 4e095941569aaee9d3fea949c02cd2210abe3b4f
First added on: Aug 26, 2024